Literature DB >> 22203592

In vitro evaluation of novel compounds against selected resistant Pseudomonas aeruginosa isolates.

Seth T Housman1, Christina Sutherland, David P Nicolau.   

Abstract

We describe the activities of RX-P763, RX-P766, RX-P770, RX-P792, RX-P793, and RX-P808 against strains of resistant Pseudomonas aeruginosa. These compounds target the large subunit of the bacterial ribosome and have broad-spectrum activities against multidrug-resistant pathogens. All compounds demonstrated in vitro activity against P. aeruginosa, with MIC(90) values of 4 to 8 μg/ml (range, 0.5 to 64). These novel compounds had narrow MIC distributions and maintained activity despite resistance phenotypes to other commonly utilized agents.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22203592      PMCID： PMC3294881          DOI： 10.1128/AAC.05944-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003.

Authors: 
Journal:  Am J Infect Control       Date:  2003-12       Impact factor: 2.918

2.  Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact.

Authors:  Leanne B Gasink; Neil O Fishman; Mark G Weiner; Irving Nachamkin; Warren B Bilker; Ebbing Lautenbach
Journal:  Am J Med       Date:  2006-06       Impact factor: 4.965

3.  Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact.

Authors:  Valerie Aloush; Shiri Navon-Venezia; Yardena Seigman-Igra; Shaltiel Cabili; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

4.  Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.

Authors:  Kathryn J Eagye; Mary A Banevicius; David P Nicolau
Journal:  Crit Care Med       Date:  2012-04       Impact factor: 7.598

5.  In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at Forty US Hospitals.

Authors:  Kathryn J Eagye; Joseph L Kuti; Christina A Sutherland; Henry Christensen; David P Nicolau
Journal:  Clin Ther       Date:  2009-11       Impact factor: 3.393

6.  National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002.

Authors:  Marilee D Obritsch; Douglas N Fish; Robert MacLaren; Rose Jung
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

7.  Overview of nosocomial infections caused by gram-negative bacilli.

Authors:  Robert Gaynes; Jonathan R Edwards
Journal:  Clin Infect Dis       Date:  2005-08-16       Impact factor: 9.079
  7 in total
  2 in total

1.  A New Natural Product Analog of Blasticidin S Reveals Cellular Uptake Facilitated by the NorA Multidrug Transporter.

Authors:  Jack R Davison; Katheryn M Lohith; Xiaoning Wang; Kostyantyn Bobyk; Sivakoteswara R Mandadapu; Su-Lin Lee; Regina Cencic; Justin Nelson; Scott Simpkins; Karen M Frank; Jerry Pelletier; Chad L Myers; Jeff Piotrowski; Harold E Smith; Carole A Bewley
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

2.  RX-P873, a Novel Protein Synthesis Inhibitor, Accumulates in Human THP-1 Monocytes and Is Active against Intracellular Infections by Gram-Positive (Staphylococcus aureus) and Gram-Negative (Pseudomonas aeruginosa) Bacteria.

Authors:  Julien M Buyck; Frédéric Peyrusson; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.